United Therapeutics
$541.70Change from previous close: −5.19%Absolute change: −$29.68
At a glance
- Revenue growth
- +10.61%
- 2025 vs 2024
- Net income growth
- +11.68%
- 2025 vs 2024
- Net margin
- 41.9%
- 2024: 41.5%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 3,183 | 2,877 | 2,328 | 1,936 | — |
| Cost of revenue | 384 | 310 | 258 | 152 | — |
| Gross profit | 2,798 | 2,568 | 2,070 | 1,785 | — |
| Selling, general and administrative | 731 | 639 | 477 | 482 | — |
| Research and development | 550 | 481 | 408 | 323 | — |
| Operating income | 1,517 | 1,448 | 1,185 | 980 | — |
| EBIT | 1,733 | 1,582 | 1,334 | 983 | — |
| EBITDA | 1,819 | 1,654 | 1,387 | 1,034 | — |
| Interest expense | 19.5 | 42.9 | 59.3 | 32.4 | — |
| Pre-tax income | 1,714 | 1,539 | 1,274 | 951 | — |
| Income tax | 379 | 344 | 290 | 223 | — |
| Net income | 1,335 | 1,195 | 985 | 727 | — |
| Net income to common shareholders | 1,335 | 1,195 | 985 | 727 | — |
| Basic EPS | 30.13 | 26.44 | 21.04 | 15.98 | — |
| Diluted EPS | 27.86 | 24.64 | 19.81 | 15.00 | — |
| Average shares (basic) | 44.3 | 45.2 | 46.8 | 45.5 | — |
| Average shares (diluted) | 47.9 | 48.5 | 49.7 | 48.5 | — |